TITLE

METHYLGENE TO RESUME DEVELOPMENT OF MGCD0103 (MOCETINOSTAT)

PUB. DATE
November 2009
SOURCE
Worldwide Biotech;Nov2009, Vol. 21 Issue 11, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that the Food and Drug Administration (FDA) in the U.S. has removed the partial clinical hold placed on MGCD0103, the proprietary selective histone deacetylase (HDAC) inhibitor for cancer from MethylGene Inc. The company is expected to restart enrollment of patients in its Phase II clinical trial. Patients with cardiac abnormalities are not allowed to be included in the trial.
ACCESSION #
44785649

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;10/19/2011, Vol. 22 Issue 203, p9 

    The article provides new briefs related to clinical trials. The result of a randomized, placebo-controlled, double-blind proof-of-concept study was reported by Ampio Pharmaceuticals Inc. which showed that allergic rhinitis is affected by intranasal Optina. The U.S. Food and Drug Administration...

  • FDA Update.  // Pharmaceutical Representative;Jun2011, Vol. 41 Issue 6, p11 

    The article offers updates relative to the U.S. Food and Drug Administration. FDA has engaged a series of studies designed to test varied ways of demonstrating the benefits and risks in direct-to-consumer (DTC) promotion of prescription drugs. FDA has approved Centocor Ortho Biotech Inc.'s...

  • Array BioPharma files IND application for Phase I cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p11 

    The article reports on the filling of an investigational new drug (IND) application by biopharmaceutical company Array BioPharma Inc. to the U.S. Food and Drug Administration (FDA). The purpose of the IND is for the initiation of a Phase I clinical trial in cancer patients with the use of the...

  • ODAC Takes AVEO to Task Over Single Phase III Trial. Serebrov, Mari // BioWorld Today;5/3/2013, Vol. 24 Issue 85, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) vote against the adequacy of single Phase III trial to support the approval of kidney cancer drug tivozanib of AVEO Oncology Inc. It notes that the NASDAQ-traded stock AVEO of the...

  • No way to save a life. Moss, Ralph W. // New Scientist;6/3/2006, Vol. 190 Issue 2554, p21 

    The article focuses on the views of the author on a decision by the U.S. Court of Appeals for the District of Columbia, in which the court ruled that terminally ill cancer patients have a constitutional right to treatments that have not yet been approved by the Food and Drug Administration. As...

  • NeoPharm reaches agreement with FDA on phase III "Precise" trial.  // PharmaWatch: Biotechnology;March 2004, Vol. 3 Issue 3, p8 

    Reports on the approval of the U.S. Food and Drug Administration to NeoPharm's Precise trial of anticancer drug. Treatment for first recurrence of glioblastoma multiforme; Comparison of overall survival, drug safety and quality of life of cancer patients; Enrollment of patients in multiple centers.

  • MyVax Trial Failure Leaves Firm Hopeful, Others Not So. Morrison, Trista // BioWorld Today;12/26/2007, Vol. 18 Issue 248, p1 

    The article reports on the Phase III trial failure of MyVax. The cancer vaccine from Genitope Corp. was not able to improve progression-free survival of patients with non-Hodgkin's lymphoma (NHL). On the other hand, company chairman and chief executive officer (CEO) Dan Denny is happy with the...

  • Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Olsen, Dana; Trøst Jørgensen, Jan // Frontiers in Oncology;May2014, Vol. 4, p1 

    Companion diagnostics (CDx) holds the promise of improving the predictability of the oncology drug development process and become an important tool for the oncologist in relation to the choice of treatment for the individual patient. A number of drug-diagnostic co-development programs have...

  • Impact of tumour volume on the potential efficacy of therapeutic vaccines. Gulley, J. L.; Madan, R. A.; Schlom, J. // Current Oncology;May2011, Vol. 18 Issue 3, pe150 

    With the recent approval by the U.S. Food and Drug Administration of the first therapeutic vaccine for cancer, the long-awaited goal of harnessing a patient's immune system to attack cancer through this modality is finally realized. However, as researchers in the field of cancer immunotherapy...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics